- Details
- Katie Murray joins Alicia Morgans to discuss reverse thermal mitomycin (JEMLYTO®) for primary chemoablation of upper tract urothelial carcinoma (UTUC) via a percutaneous nephrostomy tube. Based on results from the pivotal OLYMPUS trial, JELMYTO® is currently approved for low-grade UTUC. Dr. Murray speaks to two different methods of administration of the mitomycin gel that was allowed in this trial...
|
- Details
- Wesley Yip joins Sam Chang in discussing variant histologies in the diagnosis of upper tract urothelial carcinoma. There are some unique challenges in managing upper tract urothelial carcinoma, and there still is a persistent need to define the impact of variant histology in the upper tract on patient outcomes to affect disease management, adjuvant therapies, and follow-up strategy. The purpose of...
|
- Details
- Nima Almassi joins Sam Chang to discuss some exciting abstract highlights about upper tract urothelial carcinoma presented at the AUA 2022. Dr. Almassi shares key takeaways on studies regarding nephron-sparing treatments for upper tract disease. He also discusses research on the increasing administration of intracavitary or topical treatment. The pair also discuss new developments in the field, in...
|
- Details
- In this discussion with Sam Chang, John Gore reviews an updated analysis of the OLYMPUS trial analyzing the durability or 12-month effectiveness of patients that had a complete response to MitoGel. The OLYMPUS trial evaluated the long-term safety and durability of response to UGN-101, a mitomycin-containing reverse thermal gel, (MitoGel) as primary chemoablative treatment for low-grade upper tract...
|
- Details
- Sam Chang and Jeffrey Holzbeierlein discuss the comparative effectiveness of neoadjuvant chemotherapy for bladder cancer, as well as for upper urinary tract urothelial carcinoma. Dr. Holzbeierlein goes into depth on the background of neoadjuvant treatment for these diseases, as well as a look at the POUT trial. They also discuss future projects and exciting new studies. Biographies: Jeffrey Holzbe...
|
- Details
- Kyle Rose, SUO Clinical Fellow at Moffitt Cancer Center joins Alicia Morgans in highlighting his AUA presentation on the real-world data on the antegrade administration of reverse thermal mitomycin (JEMLYTO®) for primary chemoablation of upper tract urothelial carcinoma (UTUC). Based on results from the pivotal OLYMPUS trial, JELMYTO® is currently approved for low-grade UTUC. Dr. Rose and colleagu...
|
- Details
- Sam Chang invites Jean Hoffman-Censits to highlight the multidisciplinary work in upper tract urothelial carcinoma (UTUC) with a particular focus on patients that have high-grade UTUC being done at the Greenberg Bladder Cancer Institute at Johns Hopkins University, where Dr Hoffman-Censits is the co-director of the program. Drs. Chang and Hoffman-Censits discuss the current treatment landscape for...
|
- Details
- In this UroToday Journal Club video presentation, Christopher Wallis and Zachary Klaassen review the Journal of Urology publication "Durability of Response to Primary Chemoablation of Low-Grade Upper Tract Urothelial Carcinoma Using UGN-101, a Mitomycin-Containing Reverse Thermal Gel: OLYMPUS Trial Final Report" led by Drs Surena Matin and Seth Lerner. The goal of this study was to evaluate the lo...
|
- Details
- Wesley Yip and Sam Chang discuss the results of a multicenter trial of neoadjuvant gemcitabine and cisplatin in patients with upper tract urothelial carcinoma (UTUC) presented at the ASCO GU 2022 Cancer Symposium. This phase II multicenter trial of neoadjuvant chemotherapy with gemcitabine and cisplatin in patients with high-risk UTUC prior to extirpative surgery sought to evaluate major outcomes...
|
- Details
- Surena Matin joins Sam Chang in a state-of-the-art lecture and discussion on endoscopic management of low-grade upper tract urothelial carcinoma. Dr. Matin highlights several established therapies for the treatment of low-grade upper tract urothelial carcinoma and the two discuss ongoing trials in this disease space. Biographies: Surena F. Matin, MD, Professor, Department of Urology, Division of S...
|